AGILENT TECHNOLOGIES, INC. (A) FY2026 YTD Q2 P&L / Income Statement

Revenue by Business Segment by Geography

2025-11-01 to 2026-04-30

Swipe to see the full flow
AGILENT TECHNOLOGIES, INC. (A) FY2026 YTD Q2 P&L / Income StatementIncome statement for 2025-11-01 through 2026-04-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.SOURCESREVENUEGROSSOPERATINGPRE-TAXNETLife Sciences and Diagnostics Markets - AmericasAgilent CrossLab - AmericasAgilent CrossLab - Asia PacificAgilent CrossLab - EuropeLife Sciences and Diagnostics Markets - EuropeLife Sciences and Diagnostics Markets - Asia PacificApplied Markets - Asia PacificApplied Markets - AmericasApplied Markets - EuropeNet revenueGross profit (calculated)Cost of revenueIncome from operationsOperating expenses (calculated)Selling, general and administrativeResearch and developmentOther income (expense), net (calculated)Income before taxesNet incomeProvision for income taxesOther income (expense), net (calculated)Other income,net (calculated)$20.00 MGross profit (calculated)Gross profit(calculated)$1.94 BIncome before taxesIncome before taxes$772.00 MNet revenueNet revenue$3.63 BIncome from operationsIncome from operations$752.00 MLife Sciences and Diagnostics Markets - AmericasLife Sciences and DiagnosticsMarkets - Americas$670.00 MNet incomeNet income$644.00 MAgilent CrossLab - AmericasAgilent CrossLab - Americas$562.00 MOperating expenses (calculated)Operating expenses(calculated)$1.18 BProvision for income taxesProvision forincome taxes$128.00 MAgilent CrossLab - Asia PacificAgilent CrossLab - Asia Pacific$518.00 MSelling, general and administrativeSelling, general and administrative$941.00 MCost of revenueCost of revenue$1.70 BAgilent CrossLab - EuropeAgilent CrossLab - Europe$437.00 MResearch and developmentResearch and development$243.00 MLife Sciences and Diagnostics Markets - EuropeLife Sciences andDiagnostics Markets - Europe$417.00 MLife Sciences and Diagnostics Markets - Asia PacificLife Sciences and DiagnosticsMarkets - Asia Pacific$324.00 MApplied Markets - Asia PacificApplied Markets - Asia Pacific$313.00 MApplied Markets - AmericasApplied Markets - Americas$210.00 MApplied Markets - EuropeApplied Markets - Europe$182.00 M
Chart details

AGILENT TECHNOLOGIES, INC. (A) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2025-11-01 through 2026-04-30. View: Segments by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Net revenue
3,633,000,000 US dollars
Cost of revenue
1,697,000,000 US dollars
Gross profit (calculated)
1,936,000,000 US dollars
Operating expenses (calculated)
1,184,000,000 US dollars
Income from operations
752,000,000 US dollars
Other income (expense), net (calculated)
20,000,000 US dollars
Income before taxes
772,000,000 US dollars
Provision for income taxes
128,000,000 US dollars
Net income
644,000,000 US dollars
Agilent CrossLab - Americas
562,000,000 US dollars
Agilent CrossLab - Asia Pacific
518,000,000 US dollars
Agilent CrossLab - Europe
437,000,000 US dollars
Applied Markets - Americas
210,000,000 US dollars
Applied Markets - Asia Pacific
313,000,000 US dollars
Applied Markets - Europe
182,000,000 US dollars
Life Sciences and Diagnostics Markets - Americas
670,000,000 US dollars
Life Sciences and Diagnostics Markets - Asia Pacific
324,000,000 US dollars
Life Sciences and Diagnostics Markets - Europe
417,000,000 US dollars
Research and development
243,000,000 US dollars
Selling, general and administrative
941,000,000 US dollars

Chart connections

  • Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
  • Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
AGILENT TECHNOLOGIES, INC. (A) FY2026 YTD Q2 Revenue by Business Segment by Geography Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Gross margin

53.3%

Gross profit / revenue

Operating margin

20.7%

Operating profit / revenue

Cash conversion

84.6%

Operating cash / net income, same period

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!